Setterwalls has advised EQL Pharma in connection with listing on Nasdaq Stockholm

Setterwalls has advised EQL Pharma AB in connection with the listing of the company’s shares on Nasdaq Stockholm. The trading on Nasdaq Stockholm commenced on 4 July 2024.

EQL Pharma specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 40 niche generics launched in the Nordic markets. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets.